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Background
The first clinical trial to evaluate an effective drug for
the treatment of tuberculosis (TB) conducted in 1946 by
the Medical Research Council (MRC) under the direc-
tion of Bradford Hill is also widely regarded as the first
properly conducted randomised clinical trial in any dis-
ease area. This new treatment was shown to significantly
reduce the short term risk of death in patients with TB.
As treatment improved, death became an increasingly
uncommon outcome and change in clinical symptoms,
radiographic appearance and bacteriological response
were the commonly reported endpoints. Eventually, bac-
teriological failure and relapse became the primary end-
points of interest. Patients lost to follow-up were
excluded from the primary analysis, as were patients not
completing treatment or changing treatment for adverse
events in what would today be regarded as a per proto-
col (PP) analysis.
In recent years the first phase III trials for new TB
regimens for several decades have been initiated. Due to
the high efficacy of the standard regimen in trial set-
tings, these trials are designed as non-inferiority trials.
Guidelines recommend both an intention-to-treat (ITT)
and a PP analysis for non-inferiority trials. Classifying all
patients with missing endpoints as unfavourable, as is
recommended by the US FDA for other infectious dis-
eases, is not appropriate in the context where losses to
follow-up in the 12-18 months after treatment (when
signs and symptoms have usually ceased) could easily
exceed the true bacteriological unfavourable outcome
(approximately 5%).
Objective
In this paper, we will discuss the complexities in (1)
defining the composition of the clinical endpoint used
in a TB treatment trial with a non-inferiority design and
(2) performing the appropriate analyses. The relative
roles of bacteriology and clinical signs and symptoms as
well as the classification of patients with missing end-
points are important issues which can radically affect
the overall trial results.
Case study
We will illustrate the impact of classifying unassessable
patients and unrelated mortality in different ways from
recent trials including a regulatory submission to the
FDA.
Conclusions
There is no conservative or ‘best’ approach to defining
the endpoints for non-inferiority TB treatment trials
and considerable care needs to be taken in formulating
a precise definition. Both ITT and PP and other sensitiv-
ity analyses are essential to eliminate bias and give
robust results. Merely classifying all losses to follow-up
as unfavourable leads to meaningless results, since true
events will be swamped by random noise.
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